Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators.
Gerstein HC, et al.
Lancet. 2019 Jul 13;394(10193):131-138. doi: 10.1016/S0140-6736(19)31150-X. Epub 2019 Jun 9.
Lancet. 2019.
PMID: 31189509
Clinical Trial.
At baseline, 791 (7.9%) had macroalbuminuria and mean eGFR was 76.9 mL/min per 1.73 m(2) (SD 22.7). During a median follow-up of 5.4 years (IQR 5.1-5.9) comprising 51 820 person-years, the renal outcome developed in 848 (17.1%) participants at an incidence rate of 3.5 per …
At baseline, 791 (7.9%) had macroalbuminuria and mean eGFR was 76.9 mL/min per 1.73 m(2) (SD 22.7). During a median follow-up of 5.4 …